| 1 |
Long-term follow-up for safety and efficacy of zanubrutinib in elderly (≥80 years) treatment naïve CLL/SLL patients, including those with del(17p): Subgroup analysis from the SEQUOIA trial |
Publication PS1703 |
Poster Session 2 |
June 13, 2026, 6:45–7:45 PM CEST |
Alessandra Tedeschi |
| 2 |
Subsequent therapies and time to second progression-free survival events in chronic lymphocytic leukemia/small lymphocytic lymphoma previously treated with zanubrutinib or bendamustine-rituximab |
Publication PF601 |
Poster Session 1 |
June 12, 2026, 6:45–7:45 PM CEST |
Mazyar Shadman |
| 3 |
Zanubrutinib vs ibrutinib in treatment-naive chronic lymphocytic leukemia (CLL): Implications for interpreting fixed-duration treatment outcomes from CLL17 |
Publication PS1718 |
Poster Session 2 |
June 13, 2026, 6:45–7:45 PM CEST |
Talha Munir |
| 4 |
Associations between ECOG performance status and patient-reported outcomes in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: Post hoc analysis from the ALPINE trial |
Publication PS2492 |
Poster Session 2 |
June 13, 2026, 6:45–7:45 PM CEST |
Nicole Lamanna |
| 5 |
A longitudinal analysis of patients with CLL/SLL with impaired health-related quality of life scores at baseline who were treated with zanubrutinib versus ibrutinib: A post hoc analysis of ALPINE |
Publication PF1398 |
Poster Session 1 |
June 12, 2026, 6:45–7:45 PM CEST |
Loic Ysebaert |
| 6 |
Real-world zanubrutinib treatment patterns in CLL/SLL among US community oncology patients with prior acalabrutinib therapy |
Publication PF618 |
Poster Session 1 |
June 12, 2026, 6:45–7:45 PM CEST |
Jing-Zhou Hou |
| 7 |
Patterns of treatment utilization and sequencing across lines of therapy in Waldenström macroglobulinemia: Real-world evidence from the United States |
Publication PS2516 |
Poster Session 2 |
June 13, 2026, 6:45–7:45 PM CEST |
Prashant Kapoor |
| 8 |
Real-world comparative analysis of treatment discontinuation with covalent Bruton tyrosine kinase inhibitors in first-line chronic lymphocytic leukemia |
Publication PS1710 |
Poster Session 2 |
June 13, 2026, 6:45–7:45 PM CEST |
Nakhle Saba |
| 9 |
Real-world treatment and survival outcomes for zanubrutinib and acalabrutinib monotherapy among treatment-naïve patients with chronic lymphocytic leukemia in the United States |
Publication PF608 |
Poster Session 1 |
June 12, 2026, 6:45–7:45 PM CEST |
Ryan Jacobs |
| 10 |
A real-world comparison of treatment and survival outcomes with zanubrutinib and acalabrutinib monotherapy among patients with relapsed or refractory mantle cell lymphoma in the United States |
Publication PS2040 |
Poster Session 2 |
June 13, 2026, 6:45–7:45 PM CEST |
Yucai Wang |
| 11 |
Clinical outcomes among patients with relapsed/refractory mantle cell lymphoma receiving zanubrutinib or acalabrutinib in real-world practice in the United States |
Publication PF958 |
Poster Session 1 |
June 12, 2026, 6:45–7:45 PM CEST |
Javier Munoz |
| 12 |
Real-world impact of atrial fibrillation on cardiovascular outcomes and healthcare resource utilization in patients with chronic lymphocytic leukemia |
Publication PS2515 |
Poster Session 2 |
June 13, 2026, 6:45–7:45 PM CEST |
Rhys Williams |
| 13 |
Treatment burden among patients aged 75 or older with chronic lymphocytic leukemia and small lymphocytic lymphoma |
Publication PF605 |
Poster Session 1 |
June 12, 2026, 6:45–7:45 PM CEST |
Daniel Ermann |
| 14 |
Real-world effectiveness and safety of zanubrutinib in Waldenström macroglobulinemia: Results from the Belgian WIZARD study |
Abstract PB3600 |
— |
— |
Willem Daneels |
| 15 |
Real-world experience with zanubrutinib in chronic lymphocytic leukaemia - patient profile, treatment patterns, and safety: Preliminary analysis of French ROZALY study |
Abstract PB2898 |
— |
— |
Florian Bouclet |
| 16 |
BRUMIZE: Real-world zanubrutinib use and preliminary safety in R/R marginal zone lymphoma in Europe |
Abstract PB3632 |
— |
— |
Côme Bommier |
| 17 |
Indirect comparison of zanubrutinib vs acalabrutinib and ibrutinib efficacy in patients with treatment-naïve chronic lymphocytic leukemia |
Abstract PB2895 |
— |
— |
Mazyar Shadman |
| 18 |
Patient-reported outcomes and disease progression in chronic lymphocytic leukemia and small lymphocytic lymphoma: A systematic literature review and gap analysis |
Abstract PB2909 |
— |
— |
Loic Ysebaert |
| 19 |
Understanding patients' perspectives and preferences regarding first-line chronic lymphocytic leukemia treatment across Europe |
Abstract PB2934 |
— |
— |
Lydia Scarfò |
| 20 |
Number of deaths avoided with use of zanubrutinib versus ibrutinib for the treatment of chronic lymphocytic leukemia in Europe |
Abstract PB2944 |
— |
— |
Talha Munir |
| 21 |
Real-world intravenous immunoglobulin utilization in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with venetoclax plus obinutuzumab vs zanubrutinib |
Abstract PB2915 |
— |
— |
Nicole Lamanna |
| 22 |
Real-world outcomes among Medicare beneficiaries treated with first-line Bruton tyrosine kinase inhibitors for chronic lymphocytic leukemia |
Abstract PB2901 |
— |
— |
Daniel A. Ermann |
| 23 |
Exploring the patient and hematologist preference of treatment characteristics for chronic lymphocytic leukemia: A qualitative study in Europe |
Abstract PB4474 |
— |
— |
Lydia Scarfò |